Kineta, Inc.
KADelisted Oct 15, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001445283
Kineta, Inc. was delisted on Oct 15, 2024; its insiders filed their last Form 4 on Jul 2, 2025; 26 institutions reported holding it in 13F filings for Q2 2024, worth $388.5K in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:10 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 21, 2024 | Mar 31, 2023 | Mar 24, 2022 | Mar 31, 2021 |
| Revenue | $0 | $5.44M | $1.95M | $8.04M | $6.90M |
| Operating expenses | $13.5M | $21.2M | $43.5M | $46.8M | $62.5M |
| Research and development | $5.39M | $9.02M | $15.9M | $26.4M | $22.3M |
| Selling, general and administrative | $8.14M | $12.1M | $8.70M | $20.4M | $11.9M |
| Operating income | -$13.5M | -$15.7M | -$41.5M | -$38.7M | -$55.6M |
| Interest expense | – | $337.0K | $3.74M | $1.82M | $1.90M |
| Income tax | $0 | $0 | $0 | – | $0 |
| Net income | -$17.1M | -$14.1M | -$63.4M | -$39.5M | -$57.5M |
| EPS, basic | $-1.42 | $-1.28 | $-12.87 | – | – |
| EPS, diluted | $-1.42 | $-1.28 | $-12.87 | – | – |
| Weighted shares, basic | 12.1M | 11.1M | 4.93M | – | – |
| Weighted shares, diluted | 12.1M | 11.1M | 4.93M | – | – |
| Margins and growth | |||||
| Operating margin | – | -288.9% | -2126.5% | -481.7% | -806.7% |
| Net margin | – | -259.1% | -3246.7% | -491.1% | -833.6% |
| Revenue growth, year over year | −100.0% | +178.6% | −75.7% | +16.6% | +37.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 21, 2024 | Mar 31, 2023 | Mar 24, 2022 | Mar 31, 2021 |
| Cash and equivalents | $634.0K | $5.78M | $13.1M | $35.1M | $80.8M |
| Accounts receivable | – | – | – | $5.00M | – |
| Total current assets | $1.02M | $5.98M | $13.6M | $42.7M | $87.6M |
| Property, plant and equipment | $0 | $0 | $249.0K | $387.0K | $874.0K |
| Total assets | $1.02M | $10.3M | $17.4M | $62.9M | $114.8M |
| Accounts payable | $3.90M | $3.69M | $6.63M | $1.84M | $7.38M |
| Short-term debt | – | – | – | $5.80M | $2.89M |
| Total current liabilities | $12.9M | $7.07M | $11.5M | $22.7M | $30.9M |
| Long-term debt | – | $159.0K | $779.0K | $7.36M | $13.2M |
| Total liabilities | $12.9M | $7.22M | $12.9M | $39.4M | $58.6M |
| Shareholders' equity | -$11.9M | $3.06M | $4.57M | $23.5M | $56.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 21, 2024 | Mar 31, 2023 | Mar 24, 2022 | Mar 31, 2021 |
| Operating cash flow | -$11.6M | -$16.2M | -$19.0M | -$48.9M | -$17.9M |
| Capital expenditures | – | $0 | $71.0K | $138.0K | $246.0K |
| Free cash flow | – | -$16.2M | -$19.1M | -$49.1M | -$18.2M |
| Depreciation and amortization | $0 | $9.00K | $73.0K | $631.0K | $770.0K |
| Stock-based compensation | $1.24M | $3.85M | $5.17M | $5.29M | $2.27M |
| Investing cash flow | $0 | $331.0K | $9.27M | $3.09M | $31.0M |
| Financing cash flow | $6.35M | $8.47M | $11.8M | -$1.03M | $55.5M |
| Net change in cash | -$5.22M | -$7.41M | $2.05M | -$46.9M | $68.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 70.8% | 264.7% | 65.8% | 32.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 12, 2025 | 13.5M | +10.5% | SEC |
| Apr 25, 2025 | 13.5M | +10.5% | SEC |
| Feb 28, 2025 | 12.3M | +11.9% | SEC |
| Nov 4, 2024 | 12.3M | +18.0% | SEC |
| Aug 6, 2024 | 12.3M | +25.5% | SEC |
| May 13, 2024 | 12.3M | +29.1% | SEC |
| Mar 18, 2024 | 11.0M | +28.9% | SEC |
| Nov 6, 2023 | 10.4M | −4.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2019, from 13F share counts: 1-for-7 in Q4 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.